80yo F for general health check up. FBE: Hb 137 / WCC 13.6 / Plt 318 Blood film (pictured). Diagnosis? Further tests? Treatment? #hemepath #path #hematology #hemeisbeautiful Kamran Mirza MD PhD - کامران مرزا @AaronGoodman33 Sanam Loghavi, MD صنم لغوی 🔬🧬

IgA MM. I couldn't choose my fav 🤩 #HemePath #PathTwitter #MM

What is the risk conferred by my disease? One of the hardest questions to answer in medicine. A on the development of the International Prognostic Scoring System Molecular in MDS published today bit.ly/3aNEU64

Bab's 2 boys gofund.me/8e307c4d

Good to see that our BSH - Haematology good practice paper on the management of older patients with frailty and acute myeloid leukaemia has been published today @mikewdennis Mhairi Copland Kavita raj vp onlinelibrary.wiley.com/doi/10.1111/bj…

🩸Dr Gillian Lowe - University Hospitals Birmingham haematology consultant and Uni of Birmingham senior lecturer - has been appointed National Haematology Specialty Lead by National Institute for Health and Care Research, with the aim of offering clinical research studies to all patients as part of their care 👇 birminghamhealthpartners.co.uk/birmingham-con…

Haem trainee / junior doc / AHP - Please consider entering this year's BSH - Haematology's Crucible: 300 words on What Can Haematology Learn From History? Best 5 selected for a talk at BSH meeting 2023 + £1k prize for winner. Looking forward to judging them! b-s-h.org.uk/education/conf…

When should we move to second line in PV? According to Claire Harrison (subbing in for Dr Vannucchi) these are the recommendations. Not sure I feel as strongly about WBC - but like that elevation should be considered at 3 months. #mpnsm #ESHCMLMPN2023

The dance of of TKI toxicity - Dr Garcia-Gutierrez ESH (Haematology) #ESHCMLMPN2023

🔥🔥🔥🔥🔥🔥 MAJIC study published in Journal of Clinical Oncology Ruxolitinib (rux) Versus Best Available Therapy (BAT) for Polycythemia Vera (PV) Intolerant or Resistant to Hydroxycarbamide (HC) in a Randomized Trial ascopubs.org/doi/10.1200/JC…

Does this trial change your practice? Not for me as we were already giving GO with IC only for CBF-AML and not for non-CBF favorable risk #AMLsm such as NPM1-mutated or double/bZip CEBPA patients

Our first regional AML day. Excellent talks and stimulating discussions.UHBMyeloid Farooq A Wandroo Manoj Raghavan Dr francesca kinsella Hayder Hussein

Super pleased to see that NICE has approved Ruxolitinib for PV in England !! MPN Voice FDG published today. Let’s get on and test this drug in the front line as the Mithridate study being run jointly between 🇫🇷 and 🇬🇧 with J.J. Kiladjian

Very pleased to able to share our latest research on platelet activation in #VITT authored by Richard Buka 💙 and Sam Montague from Bham Platelet Group and @ICVS_UoB published in @BloodJournal yesterday. We show that PF4 itself activates platelets via the TPO receptor c-MPL.

Excellent presentation by Vaishali o risk factors and outcomes of CAR T manufacturing failure. #ASH2023

Chromatin patterns 🧵 [1] How many times have you heard phrases like: "Fine chromatin" "Dotted like with a pencil" "Smooth chromatin" "Clumped chromatin" "like a football (some of y'all may call it a soccer ball)"...? What do they mean and how do you make sense of it all? How

Strategies to reduce relapse risk in patients undergoing allogeneic stem cell transplantation for #AML #leusm |British Journal of Haematology | Wiley Online Library onlinelibrary.wiley.com/doi/full/10.11…

Are you a clinician who sees patients with secondary polycythaemia? Are you frustrated by the lack of an evidence base for treating these patients? Does your practise differ from your colleagues when treating these patients?

And it's GOOOOOOOLD for Megan Richter! Oooh yes!! What a morning for the Brits on the bridge. #ParalympicsGB 🥇#ParaTriathlon